SOURCE: CorTronix(TM) Biomedical Advancement Technologies, Inc.
DORAL, FL--(Marketwired - May 12, 2014) - CorTronix™ Biomedical Advancement Technologies, Inc. ("CorTronix" or "the Company") (OTCQB: CBAT) (PINKSHEETS: CBAT) a BioMedical device developer and manufacturer of next generation Telemetric Medical Devices, announces today that it completed the development of its CorTab; a cutting edge medical telemetry system for cardiac patients. CorTronix President Mr. Yoel Palomino stated, "This system is ready to go and we will begin pre-clinical testing of the device on live patients in the very near term. I'm proud to unveil this unique, single platform device that will potentially replace the large bulky units commonly found in hospitals today." He continued to say, "Our Saudi Arabia based partner will take receipt of several samples of the CorTab over the next couple of weeks and we will begin distance testing of our product as well."
CorTronix is a Presidents Circle Corporate Member of the American Telemedicine Association (ATA) along with some of the world's greatest companies such as Verizon, Bosch, Philips, Alere, and GlobalMed, to name a few. InformationWeek magazine recently reported that the Global market for Telemedicine is headed for $27 Billion by 2016 and expected to keep growing. The fastest growing segment within the telemedicine industry is the technology sector, which by itself will account for nearly half of overall market.
Mr. Palomino finished by saying, "After spending the last few years in the development stage working in the design, programming and system integration of CorTab we are very happy to deliver to our shareholders and partners the first component of the CorTronix Telemedicine System."
About CorTronix™ Biomedical Advancement Technologies, Inc.
CorTronix™ Biomedical Advancement Technologies, Inc. ("CorTronix" or the "Company") is a BioMedical Corporation with a core competency in Mobile Cardio Devices. The Company is creating a complete product line that will consist of multiple revolutionary mobile devices with the capacity to acquire and process patient's data through a consolidated "Single Source" Network.
CorTronix™ integrates existing medical procedures with cutting edge wireless technology through the Company's proprietary Network (CorLink™) with the intent of creating the next generation Telemetric Medical Devices. The Company is in the final stages of developing the infrastructure of this Global Health Network that will significantly increase the overall ability for Medical Professionals to properly diagnose and analyze Patients data remotely and in real time. CorTronix Telemetric medical devices are the future of remote patient monitoring and bring an unprecedented advantage to doctors and distant patients. The software being developed for each of the CorTronix products, is being designed from the ground up to take advantage of the powerful hardware platform and its integrated ECG acquisition system. Each of CorTronix products are equipped with a designated ECG acquisition and conversion integrated circuit, that reduces circuit design costs and PCB size by 200%, this in turn will translate into elegant and powerful medical telemetry devices.
Safe Harbor Statement
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.